Regulus Therapeutics Inc.

NasdaqCM:RGLS

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Pharmaceuticals

Location

United States

Market Cap

USD 545.56 M

Share Price

USD 7.88

Avg Daily Volume

2,047,107

Change (1 day)

-4.02%

Change (1 year)

212.70%

Change (YTD)

398.73%

Regulus Therapeutics Inc. Share Price Year-To-Date (YTD) return on June 20, 2025: 398.73%

Regulus Therapeutics Inc. Share Price Year-To-Date (YTD) return is 398.73% on June 20, 2025. Share price reflects current trading price of a company's stock; influenced by market dynamics and company performance. Year-to-Date (YTD) return is is the percentage change in the price of a stock from the start of the calendar year up to the current date, it shows how much the stock has gained or lost since the beginning of the year.

Regulus Therapeutics Inc. 52-week low Share Price is USD 8.30 on June 20, 2025, which is 5.33% above the current Share Price.
Regulus Therapeutics Inc. 52-week low Share Price is USD 0.97 on June 20, 2025, which is -87.69% below the current Share Price.
Regulus Therapeutics Inc. average Share Price for the last 52 weeks is USD 2.50.

Daily

From:

To:

Zoom:

Key data

Date	Share Price Year-To-Date (YTD) return	Price to Earnings Ratio (P/E)	Price to Book Ratio (P/B)	Price to Sales Ratio (P/S)

NasdaqCM: RGLS

Regulus Therapeutics Inc.

CEO	Mr. Joseph P. Hagan M.B.A.
IPO Date	Oct. 9, 2012
Location	United States
Headquarters	4224 Campus Point Court
Employees	34
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Pharmaceuticals

Description

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.